MyJournals Home  

RSS FeedsCan Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study (European Urology Oncology)

 
 

14 may 2020 16:28:55

 
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study (European Urology Oncology)
 


We reported a significant association between fibroblast growth factor receptor-3 (FGFR3) gene expression and pathological complete response to neoadjuvant pembrolizumab. This result was counterbalanced by the lack of significance when using more comprehensive FGFR3 activity signatures or DNA alterations (mutations/fusions). Similar results were obtained with neoadjuvant chemotherapy. FGFR3 alterations should not disqualify patients for inclusion in neoadjuvant immunotherapy or chemoimmunotherapy studies.


 
67 viewsCategory: Oncology, Urology
 
Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma (European Urology Oncology)
 
 
blog comments powered by Disqus


MyJournals.org
The latest issues of all your favorite science journals on one page

Username:
Password:

Register | Retrieve

Search:


Copyright © 2008 - 2020 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten